PTPI

SEC source: 0001104659-26-071048 · tm2617013-3_4seq1.xml · nonDerivative · entry 1

Boctor Fady · CIK 0001833394 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 894,986

F1 · shares: Represents restricted shares ("Shares") of common stock, par value $0.0001 per share, of the Issuer. 50% of the Shares vested on the date of grant and the remaining 50% will vest on the six-month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date.

F1 · price: Represents restricted shares ("Shares") of common stock, par value $0.0001 per share, of the Issuer. 50% of the Shares vested on the date of grant and the remaining 50% will vest on the six-month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date.

SEC source: 0001104659-26-071039 · tm2617013-2_4seq1.xml · nonDerivative · entry 1

Bernstein Bruce · CIK 0001665472 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,762,334

F1 · shares: Represents restricted shares ("Shares") of common stock, par value $0.0001 per share, of the Issuer. 50% of the Shares vested on the date of grant and the remaining 50% will vest on the six-month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date.

F1 · price: Represents restricted shares ("Shares") of common stock, par value $0.0001 per share, of the Issuer. 50% of the Shares vested on the date of grant and the remaining 50% will vest on the six-month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date.

SEC source: 0001104659-26-071038 · tm2617013-4_4seq1.xml · nonDerivative · entry 1

Silverman Joshua · CIK 0001524858 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,790,450

F1 · shares: Represents restricted shares ("Shares") of common stock, par value $0.0001 per share, of the Issuer. 50% of the Shares vested on the date of grant and the remaining 50% will vest on the six-month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date.

F1 · price: Represents restricted shares ("Shares") of common stock, par value $0.0001 per share, of the Issuer. 50% of the Shares vested on the date of grant and the remaining 50% will vest on the six-month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date.

SEC source: 0001104659-26-071436 · tm2617013-1_4seq1.xml · nonDerivative · entry 1

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 881,333

F1 · shares: Represents restricted shares ("Shares") of common stock, par value $0.0001 per share, of the Issuer. 50% of the Shares vested on the date of grant and the remaining 50% will vest on the six-month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date.

F1 · price: Represents restricted shares ("Shares") of common stock, par value $0.0001 per share, of the Issuer. 50% of the Shares vested on the date of grant and the remaining 50% will vest on the six-month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date.

SEC source: 0001104659-26-000238 · tm261718-4_4seq1.xml · nonDerivative · entry 1

Silverman Joshua · CIK 0001524858 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,415,450

F1 · shares: Represents Restricted Stock Units ("RSUs"). 50% of the RSUs vested on the date of grant and the remaining 50% will vest on the six month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date. Each RSU represents the right to receive one share of common stock, par value $0.0001 per share (the "Common Stock"), of the Issuer.

F1 · price: Represents Restricted Stock Units ("RSUs"). 50% of the RSUs vested on the date of grant and the remaining 50% will vest on the six month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date. Each RSU represents the right to receive one share of common stock, par value $0.0001 per share (the "Common Stock"), of the Issuer.

F2 · balance_after: Amounts adjusted for the Issuer's 1-for-25 reverse stock split of the Issuer's Common Stock, effective as of 4:05 p.m. (New York time) on April 30, 2025.

SEC source: 0001104659-26-000237 · tm261718-3_4seq1.xml · nonDerivative · entry 1

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 506,333

F1 · shares: Represents Restricted Stock Units ("RSUs"). 50% of the RSUs vested on the date of grant and the remaining 50% will vest on the six month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date. Each RSU represents the right to receive one share of common stock, par value $0.0001 per share (the "Common Stock"), of the Issuer.

F1 · price: Represents Restricted Stock Units ("RSUs"). 50% of the RSUs vested on the date of grant and the remaining 50% will vest on the six month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date. Each RSU represents the right to receive one share of common stock, par value $0.0001 per share (the "Common Stock"), of the Issuer.

F2 · balance_after: Amounts adjusted for the Issuer's 1-for-25 reverse stock split of the Issuer's Common Stock, effective as of 4:05 p.m. (New York time) on April 30, 2025.

SEC source: 0001104659-26-000233 · tm261718-1_4seq1.xml · nonDerivative · entry 1

Bernstein Bruce · CIK 0001665472 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,887,334

F1 · shares: Represents Restricted Stock Units ("RSUs"). 50% of the RSUs vested on the date of grant and the remaining 50% will vest on the six month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date. Each RSU represents the right to receive one share of common stock, par value $0.0001 per share (the "Common Stock"), of the Issuer.

F1 · price: Represents Restricted Stock Units ("RSUs"). 50% of the RSUs vested on the date of grant and the remaining 50% will vest on the six month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date. Each RSU represents the right to receive one share of common stock, par value $0.0001 per share (the "Common Stock"), of the Issuer.

F2 · balance_after: Amounts adjusted for the Issuer's 1-for-25 reverse stock split of the Issuer's Common Stock, effective as of 4:05 p.m. (New York time) on April 30, 2025.

SEC source: 0001104659-26-001417 · tm261718-2_4seq1.xml · nonDerivative · entry 1

Boctor Fady · CIK 0001833394 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 519,986

F1 · shares: Represents Restricted Stock Units ("RSUs"). 50% of the RSUs vested on the date of grant and the remaining 50% will vest on the six month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date. Each RSU represents the right to receive one share of common stock, par value $0.0001 per share (the "Common Stock"), of the Issuer.

F1 · price: Represents Restricted Stock Units ("RSUs"). 50% of the RSUs vested on the date of grant and the remaining 50% will vest on the six month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date. Each RSU represents the right to receive one share of common stock, par value $0.0001 per share (the "Common Stock"), of the Issuer.

F2 · balance_after: Amounts adjusted for the Issuer's 1-for-25 reverse stock split of the Issuer's Common Stock, effective as of 4:05 p.m. (New York time) on April 30, 2025.

SEC source: 0001104659-25-016203 · tm257316-5_4seq1.xml · nonDerivative · entry 1

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 158,314

F1 · price: Represents a grant of restricted shares of common stock, par value $0.0001 per share, of the Issuer granted under the Petros Pharmaceuticals, Inc. Amended and Restated 2020 Omnibus Incentive Compensation Plan, as amended. 50% of the shares vest on the first anniversary of the date of grant and the remaining shares vest on the second anniversary on the date of grant, provided that the Reporting Person continues to provide service to the Issuer on the applicable vesting date.

SEC source: 0001104659-25-016202 · tm257316-4_4seq1.xml · nonDerivative · entry 1

Arnold Mitchell · CIK 0001841497 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,000

F1 · price: Represents a grant of restricted shares of common stock, par value $0.0001 per share, of the Issuer granted under the Petros Pharmaceuticals, Inc. Amended and Restated 2020 Omnibus Incentive Compensation Plan, as amended. 50% of the shares vest on the first anniversary of the date of grant and the remaining shares vest on the second anniversary on the date of grant, provided that the Reporting Person continues to provide service to the Issuer on the applicable vesting date.

SEC source: 0001104659-25-016201 · tm257316-3_4seq1.xml · nonDerivative · entry 1

Silverman Joshua · CIK 0001524858 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,011,237

F1 · price: Represents a grant of restricted shares of common stock, par value $0.0001 per share, of the Issuer granted under the Petros Pharmaceuticals, Inc. Amended and Restated 2020 Omnibus Incentive Compensation Plan, as amended. 50% of the shares vest on the first anniversary of the date of grant and the remaining shares vest on the second anniversary on the date of grant, provided that the Reporting Person continues to provide service to the Issuer on the applicable vesting date.

SEC source: 0001104659-25-016200 · tm257316-2_4seq1.xml · nonDerivative · entry 1

Boctor Fady · CIK 0001833394 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 499,645

F1 · price: Represents a grant of restricted shares of common stock, par value $0.0001 per share, of the Issuer granted under the Petros Pharmaceuticals, Inc. Amended and Restated 2020 Omnibus Incentive Compensation Plan, as amended. 50% of the shares vest on the first anniversary of the date of grant and the remaining shares vest on the second anniversary on the date of grant, provided that the Reporting Person continues to provide service to the Issuer on the applicable vesting date.

SEC source: 0001104659-25-016197 · tm257316-1_4seq1.xml · nonDerivative · entry 1

Bernstein Bruce · CIK 0001665472 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 308,346

F1 · price: Represents a grant of restricted shares of common stock, par value $0.0001 per share, of the Issuer granted under the Petros Pharmaceuticals, Inc. Amended and Restated 2020 Omnibus Incentive Compensation Plan, as amended. 50% of the shares vest on the first anniversary of the date of grant and the remaining shares vest on the second anniversary on the date of grant, provided that the Reporting Person continues to provide service to the Issuer on the applicable vesting date.

SEC source: 0001104659-23-129255 · tm2333705-3_4seq1.xml · derivative · entry 1

Bernstein Bruce · CIK 0001665472 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2033-12-21

F1 · derivative.exercise_date: The stock options will vest on April 10, 2024, provided that the Reporting Person has continued to provide services to Petros Pharmaceuticals, Inc. through the vesting date.

SEC source: 0001104659-23-129254 · tm2333705-6_4seq1.xml · derivative · entry 2

Boctor Fady · CIK 0001833394 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,533

Underlying: Common Stock · 54,533 shares

Expires 2033-12-21

F1 · derivative.exercise_date: The stock options vested 50% upon the date of grant, and the remainder vests upon the achievement of certain performance goals, provided that the Reporting Person has continued to provide services to the Company through the vesting date.

SEC source: 0001104659-23-129254 · tm2333705-6_4seq1.xml · nonDerivative · entry 1

Boctor Fady · CIK 0001833394 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,645

SEC source: 0001104659-23-129252 · tm2333705-2_4seq1.xml · derivative · entry 1

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2033-12-21

F1 · derivative.exercise_date: The stock options will vest on April 10, 2024, provided that the Reporting Person has continued to provide services to Petros Pharmaceuticals, Inc. through the vesting date.

SEC source: 0001104659-23-129251 · tm2333705-5_4seq1.xml · derivative · entry 1

Arnold Mitchell · CIK 0001841497 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2033-12-21

F1 · derivative.exercise_date: The stock options vested 100% upon grant.

SEC source: 0001104659-23-129250 · tm2333705-1_4seq1.xml · derivative · entry 1

Silverman Joshua · CIK 0001524858 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2033-12-21

F1 · derivative.exercise_date: The stock options will vest on April 10, 2024, provided that the Reporting Person has continued to provide services to Petros Pharmaceuticals, Inc. through the vesting date.

SEC source: 0001104659-23-129247 · tm2333705-4_4seq1.xml · derivative · entry 1

Bradley Greg · CIK 0001833504 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2033-12-21

F1 · derivative.exercise_date: The stock options will vest on April 10, 2024, provided that the Reporting Person has continued to provide services to Petros Pharmaceuticals, Inc. through the vesting date.

SEC source: 0001104659-23-053227 · tm2313909-4_4seq1.xml · derivative · entry 2

Bradley Greg · CIK 0001833504 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,050 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock of the Issuer.

F1 · shares: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split.

F2 · derivative.exercise_date: On April 7, 2022, the reporting person was granted 6,050 restricted stock units, vesting on April 7, 2023, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on April 26, 2023.

F2 · derivative.expiration_date: On April 7, 2022, the reporting person was granted 6,050 restricted stock units, vesting on April 7, 2023, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on April 26, 2023.

F1 · derivative.underlying_shares: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split.

SEC source: 0001104659-23-053227 · tm2313909-4_4seq1.xml · nonDerivative · entry 1

Bradley Greg · CIK 0001833504 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,314

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split.

F2 · price: On April 7, 2022, the reporting person was granted 6,050 restricted stock units, vesting on April 7, 2023, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on April 26, 2023.

F1 · balance_after: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split.

SEC source: 0001104659-23-053226 · tm2313909-3_4seq1.xml · derivative · entry 2

Bernstein Bruce · CIK 0001665472 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,050 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock of the Issuer.

F1 · shares: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split.

F2 · derivative.exercise_date: On April 7, 2022, the reporting person was granted 6,050 restricted stock units, vesting on April 7, 2023, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on April 26, 2023.

F2 · derivative.expiration_date: On April 7, 2022, the reporting person was granted 6,050 restricted stock units, vesting on April 7, 2023, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on April 26, 2023.

F1 · derivative.underlying_shares: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split.

SEC source: 0001104659-23-053226 · tm2313909-3_4seq1.xml · nonDerivative · entry 1

Bernstein Bruce · CIK 0001665472 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,346

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split.

F2 · price: On April 7, 2022, the reporting person was granted 6,050 restricted stock units, vesting on April 7, 2023, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on April 26, 2023.

F1 · balance_after: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split.

SEC source: 0001104659-23-053225 · tm2313909-2_4seq1.xml · derivative · entry 2

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,050 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock of the Issuer.

F1 · shares: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split.

F2 · derivative.exercise_date: On April 7, 2022, the reporting person was granted 6,050 restricted stock units, vesting on April 7, 2023, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on April 26, 2023.

F2 · derivative.expiration_date: On April 7, 2022, the reporting person was granted 6,050 restricted stock units, vesting on April 7, 2023, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on April 26, 2023.

F1 · derivative.underlying_shares: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split.

SEC source: 0001104659-23-053225 · tm2313909-2_4seq1.xml · nonDerivative · entry 1

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,314

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split.

F2 · price: On April 7, 2022, the reporting person was granted 6,050 restricted stock units, vesting on April 7, 2023, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on April 26, 2023.

F1 · balance_after: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split.

SEC source: 0001104659-23-053224 · tm2313909-1_4seq1.xml · derivative · entry 2

Silverman Joshua · CIK 0001524858 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,722 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock of the Issuer.

F1 · shares: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split.

F2 · derivative.exercise_date: On April 7, 2022, the reporting person was granted 6,722 restricted stock units, vesting on April 7, 2023, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on April 26, 2023.

F2 · derivative.expiration_date: On April 7, 2022, the reporting person was granted 6,722 restricted stock units, vesting on April 7, 2023, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on April 26, 2023.

F1 · derivative.underlying_shares: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split.

SEC source: 0001104659-23-053224 · tm2313909-1_4seq1.xml · nonDerivative · entry 1

Silverman Joshua · CIK 0001524858 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,237

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split.

F2 · price: On April 7, 2022, the reporting person was granted 6,722 restricted stock units, vesting on April 7, 2023, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on April 26, 2023.

F1 · balance_after: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split.

SEC source: 0001104659-23-044713 · tm2312600-4_4seq1.xml · derivative · entry 1

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,000

Underlying: Common Stock · 39,000 shares

Expires 2033-04-10

F1 · derivative.exercise_date: The stock options will vest on the one-year anniversary of the date of grant, provided that the Reporting Person has continued to provide services to Petros Pharmaceuticals, Inc. (the "Company") through the vesting date.

SEC source: 0001104659-23-044712 · tm2312600-3_4seq.xml · derivative · entry 1

Silverman Joshua · CIK 0001524858 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,000

Underlying: Common Stock · 39,000 shares

Expires 2033-04-10

F1 · derivative.exercise_date: The stock options will vest on the one-year anniversary of the date of grant, provided that the Reporting Person has continued to provide services to Petros Pharmaceuticals, Inc. (the "Company") through the vesting date.

SEC source: 0001104659-23-044711 · tm2312600-2_4seq1.xml · derivative · entry 1

Bradley Greg · CIK 0001833504 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,000

Underlying: Common Stock · 39,000 shares

Expires 2033-04-10

F1 · derivative.exercise_date: The stock options will vest on the one-year anniversary of the date of grant, provided that the Reporting Person has continued to provide services to Petros Pharmaceuticals, Inc. (the "Company") through the vesting date.

SEC source: 0001104659-23-044709 · tm2312600-1_4seq1.xml · derivative · entry 1

Bernstein Bruce · CIK 0001665472 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,000

Underlying: Common Stock · 39,000 shares

Expires 2033-04-10

F1 · derivative.exercise_date: The stock options will vest on the one-year anniversary of the date of grant, provided that the Reporting Person has continued to provide services to Petros Pharmaceuticals, Inc. (the "Company") through the vesting date.

SEC source: 0001104659-23-006546 · tm234334-3_4seq1.xml · derivative · entry 2

Silverman Joshua · CIK 0001524858 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,515 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock of the Issuer.

F1 · shares: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split.

F2 · derivative.exercise_date: On December 22, 2021, the reporting person was granted 2,515 restricted stock units, vesting on December 22, 2022, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on January 20, 2023.

F2 · derivative.expiration_date: On December 22, 2021, the reporting person was granted 2,515 restricted stock units, vesting on December 22, 2022, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on January 20, 2023.

F1 · derivative.underlying_shares: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split.

SEC source: 0001104659-23-006546 · tm234334-3_4seq1.xml · nonDerivative · entry 1

Silverman Joshua · CIK 0001524858 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,515

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split.

F2 · price: On December 22, 2021, the reporting person was granted 2,515 restricted stock units, vesting on December 22, 2022, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on January 20, 2023.

F1 · balance_after: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split.

SEC source: 0001104659-23-006547 · tm234334-4_4seq1.xml · derivative · entry 2

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,264 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock of the Issuer.

F1 · shares: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split.

F2 · derivative.exercise_date: On December 22, 2021, the reporting person was granted 2,264 restricted stock units, vesting on December 22, 2022, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on January 20, 2023.

F2 · derivative.expiration_date: On December 22, 2021, the reporting person was granted 2,264 restricted stock units, vesting on December 22, 2022, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on January 20, 2023.

F1 · derivative.underlying_shares: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split.

SEC source: 0001104659-23-006547 · tm234334-4_4seq1.xml · nonDerivative · entry 1

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,264

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split.

F2 · price: On December 22, 2021, the reporting person was granted 2,264 restricted stock units, vesting on December 22, 2022, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on January 20, 2023.

F1 · balance_after: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split.

SEC source: 0001104659-23-006542 · tm234334-1_4seq1.xml · derivative · entry 2

Bernstein Bruce · CIK 0001665472 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,264 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock of the Issuer.

F1 · shares: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split.

F2 · derivative.exercise_date: On December 22, 2021, the reporting person was granted 2,264 restricted stock units, vesting on December 22, 2022, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on January 20, 2023.

F2 · derivative.expiration_date: On December 22, 2021, the reporting person was granted 2,264 restricted stock units, vesting on December 22, 2022, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on January 20, 2023.

F1 · derivative.underlying_shares: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split.

SEC source: 0001104659-23-006542 · tm234334-1_4seq1.xml · nonDerivative · entry 1

Bernstein Bruce · CIK 0001665472 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,296

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split.

F2 · price: On December 22, 2021, the reporting person was granted 2,264 restricted stock units, vesting on December 22, 2022, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on January 20, 2023.

F1 · balance_after: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split.

SEC source: 0001104659-23-006545 · tm234334-2_4seq1.xml · derivative · entry 2

Bradley Greg · CIK 0001833504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,264 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock of the Issuer.

F1 · shares: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split.

F2 · derivative.exercise_date: On December 22, 2021, the reporting person was granted 2,264 restricted stock units, vesting on December 22, 2022, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on January 20, 2023.

F2 · derivative.expiration_date: On December 22, 2021, the reporting person was granted 2,264 restricted stock units, vesting on December 22, 2022, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on January 20, 2023.

F1 · derivative.underlying_shares: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split.

SEC source: 0001104659-23-006545 · tm234334-2_4seq1.xml · nonDerivative · entry 1

Bradley Greg · CIK 0001833504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,264

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split.

F2 · price: On December 22, 2021, the reporting person was granted 2,264 restricted stock units, vesting on December 22, 2022, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on January 20, 2023.

F1 · balance_after: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split.

SEC source: 0001104659-22-044717 · tm2212468d4_4.xml · derivative · entry 1

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,505

Underlying: Common Stock · 60,505 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock of the Issuer.

F2 · derivative.exercise_date: The restricted stock units vest on the one-year anniversary of the date of grant, subject to the reporting person's employment on that date.

F2 · derivative.expiration_date: The restricted stock units vest on the one-year anniversary of the date of grant, subject to the reporting person's employment on that date.

SEC source: 0001104659-22-044715 · tm2212468d3_4.xml · derivative · entry 1

Silverman Joshua · CIK 0001524858 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,227

Underlying: Common Stock · 67,227 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock of the Issuer.

F2 · derivative.exercise_date: The restricted stock units vest on the one-year anniversary of the date of grant, subject to the reporting person's employment on that date.

F2 · derivative.expiration_date: The restricted stock units vest on the one-year anniversary of the date of grant, subject to the reporting person's employment on that date.

SEC source: 0001104659-22-044713 · tm2212468d2_4.xml · derivative · entry 1

Bradley Greg · CIK 0001833504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,505

Underlying: Common Stock · 60,505 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock of the Issuer.

F2 · derivative.exercise_date: The restricted stock units vest on the one-year anniversary of the date of grant, subject to the reporting person's employment on that date.

F2 · derivative.expiration_date: The restricted stock units vest on the one-year anniversary of the date of grant, subject to the reporting person's employment on that date.

SEC source: 0001104659-22-044711 · tm2212468d1_4.xml · derivative · entry 1

Bernstein Bruce · CIK 0001665472 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,505

Underlying: Common Stock · 60,505 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock of the Issuer.

F2 · derivative.exercise_date: The restricted stock units vest on the one-year anniversary of the date of grant, subject to the reporting person's employment on that date.

F2 · derivative.expiration_date: The restricted stock units vest on the one-year anniversary of the date of grant, subject to the reporting person's employment on that date.

SEC source: 0001104659-22-000036 · tm2136682-1_4seq1.xml · derivative · entry 2

SHULMAN JOHN D · CIK 0001208886 · Director · 10% owner

JCP III SM AIV, L.P. · CIK 0001835386 · 10% owner

METP Holdings LLC · CIK 0001836319 · 10% owner

Juggernaut Partners III GP, L.P. · CIK 0001835421 · 10% owner

Juggernaut Partners III GP, Ltd. · CIK 0001835433 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 109,329

Underlying: Common Stock · 109,329 shares

Expires 2026-12-28

F1 · ownership.nature: See Note (1) in Exhibit 99.1.

SEC source: 0001104659-22-000036 · tm2136682-1_4seq1.xml · nonDerivative · entry 1

SHULMAN JOHN D · CIK 0001208886 · Director · 10% owner

JCP III SM AIV, L.P. · CIK 0001835386 · 10% owner

METP Holdings LLC · CIK 0001836319 · 10% owner

Juggernaut Partners III GP, L.P. · CIK 0001835421 · 10% owner

Juggernaut Partners III GP, Ltd. · CIK 0001835433 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 5,703,544

F1 · balance_after: See Note (1) in Exhibit 99.1.

F1 · ownership.nature: See Note (1) in Exhibit 99.1.

SEC source: 0001104659-22-002307 · tm222320d4_4.xml · derivative · entry 1

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,642

Underlying: Common Stock · 22,642 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock of the Issuer.

F2 · derivative.exercise_date: The restricted stock units vest on the one year anniversary of the date of grant, subject to the reporting person's employment on that date

F2 · derivative.expiration_date: The restricted stock units vest on the one year anniversary of the date of grant, subject to the reporting person's employment on that date

SEC source: 0001104659-22-002306 · tm222320d3_4.xml · derivative · entry 1

Silverman Joshua · CIK 0001524858 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,156

Underlying: Common Stock · 25,156 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock of the Issuer.

F2 · derivative.exercise_date: The restricted stock units vest on the one year anniversary of the date of grant, subject to the reporting person's employment on that date

F2 · derivative.expiration_date: The restricted stock units vest on the one year anniversary of the date of grant, subject to the reporting person's employment on that date

SEC source: 0001104659-22-002304 · tm222320d2_4.xml · derivative · entry 1

Bradley Greg · CIK 0001833504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,642

Underlying: Common Stock · 22,642 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock of the Issuer.

F2 · derivative.exercise_date: The restricted stock units vest on the one year anniversary of the date of grant, subject to the reporting person's employment on that date

F2 · derivative.expiration_date: The restricted stock units vest on the one year anniversary of the date of grant, subject to the reporting person's employment on that date

SEC source: 0001104659-22-002303 · tm222320d1_4.xml · derivative · entry 1

Bernstein Bruce · CIK 0001665472 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,642

Underlying: Common Stock · 22,642 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock of the Issuer.

F2 · derivative.exercise_date: The restricted stock units vest on the one year anniversary of the date of grant, subject to the reporting person's employment on that date

F2 · derivative.expiration_date: The restricted stock units vest on the one year anniversary of the date of grant, subject to the reporting person's employment on that date